Issued: Wednesday 26 October 2011, London, UK

- EPS 28.5p +1% before major restructuring*
- Dividend +6% to 17p
- 2011 share buyback expectations increased to up to £2.3 billion

Full details of GSK's results for the third quarter of 2011 can be found in the Investors section of GSK.com.

Q3 2011 results announcement (PDF)

GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2010.